The mRNA vaccine Technology Transfer Programme was set up to address the inequalities in access to COVID-19 vaccines in low- and middle-income countries, especially in Africa. Formally established in July 2021, the objective of the Programme is to increase access to mRNA vaccines made closer to home by establishing manufacturing capacity and to develop skilled human capital in regions where mRNA vaccine manufacturing capacity is established or can be enhanced.

In August 2022, scientists at Biogeneric Pharma, Egypt traveled to Afrigen for training. For the team, this was the first training in mRNA technology.